Barclays Has Lowered Expectations for Definitive Healthcare (NASDAQ:DH) Stock Price

Definitive Healthcare (NASDAQ:DH - Free Report) had its target price lowered by Barclays from $4.00 to $3.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has an underweight rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Stephens assumed coverage on shares of Definitive Healthcare in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC restated a "hold" rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $5.35.

Definitive Healthcare Stock Down 5.1 %

Definitive Healthcare stock traded down $0.14 during trading hours on Monday, hitting $2.63. The stock had a trading volume of 905,214 shares, compared to its average volume of 970,883. The stock's 50-day moving average price is $4.55 and its 200-day moving average price is $4.45. Definitive Healthcare has a 12-month low of $2.58 and a 12-month high of $8.71. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $303.83 million, a P/E ratio of -0.85, a price-to-earnings-growth ratio of 4.06 and a beta of 1.45.

Remove Ads

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The business had revenue of $62.29 million for the quarter, compared to analysts' expectations of $60.60 million. Equities research analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in DH. Price T Rowe Associates Inc. MD grew its holdings in Definitive Healthcare by 20.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock valued at $85,000 after purchasing an additional 3,496 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Definitive Healthcare by 9.7% in the fourth quarter. Principal Financial Group Inc. now owns 43,960 shares of the company's stock worth $181,000 after buying an additional 3,874 shares during the period. Rhumbline Advisers lifted its stake in shares of Definitive Healthcare by 5.2% during the 4th quarter. Rhumbline Advisers now owns 81,316 shares of the company's stock worth $334,000 after acquiring an additional 4,034 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Definitive Healthcare by 18.1% during the fourth quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company's stock valued at $120,000 after purchasing an additional 4,500 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Definitive Healthcare by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company's stock worth $334,000 after buying an additional 4,748 shares during the period. Hedge funds and other institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.